Clinical Trials

Accrual Status
Limit to SWOG Trials

1027 Results

Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S1900K

A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

Status Notes
S1900K will open to accrual December 18, 2023, effective 3:00 p.m. EST.
Research Committee(s)
LungMAP
Activated
12-18-2023
ClinicalTrials.gov Registry Number
NCT06031688
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2213

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Status Notes
S2213 is open to patient accrual December 01, 2023, effective 12:00 p.m. Pacific Time.
Research Committee(s)
Myeloma
Activated
12-01-2023
ClinicalTrials.gov Registry Number
06022939
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer

Status Notes
This study is open to patient accrual effective 10/30/23.
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10-30-2023
ClinicalTrials.gov Registry Number
06058377
Open
Phase
Accrual
2%
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Status Notes
Active as of 08/14/2023, 12 PM PST.
Research Committee(s)
Genitourinary Cancer
Activated
08-14-2023
ClinicalTrials.gov Registry Number
NCT05806515
Open
Phase
Accrual
3%
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)

Status Notes
This study is active in SWOG as of July 21, 2023.
Research Committee(s)
Breast Cancer
Activated
07-21-2023
ClinicalTrials.gov Registry Number
NCT05929768
Open
Phase
Accrual
3%
SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma

Status Notes
S2207 will open to accrual June 30, 2023, effective 3:00 p.m. EST.
Research Committee(s)
Lymphoma
Activated
06-30-2023
ClinicalTrials.gov Registry Number
05890352